ArticleTheranostics2025
P2X7R antagonism suppresses long-lasting brain hyperexcitability following traumatic brain injury in mice.
Abstract read
In one paragraph
Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- P2X7 receptor-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics.Brain : a journal of neurology · 2026Article
- CD11c + microglia: From basic research to clinical application.Neural regeneration research · 2026Article
- Mesenchymal stem cells as cellular factories for targeted P2X7 blockade after traumatic brain injury.Neuroprotection (Chichester, England) · 2026Article
- P2X7 Signaling in Neuroinflammation: Glial Crosstalk, Redox Integration, and Therapeutic Targeting.Journal of molecular neuroscience : MN · 2026Review
- P2X7 receptor and neuroinflammation in neurodegenerative disorders: an autoradiography study with [ 18 F]JNJ-64413739.Nuclear medicine communications · 2026Article
- Microglia and neuroinflammation: function, heterogeneity, and crosstalk.Cellular & molecular immunology · 2026Review
- The purinergic receptor P2rx7 mediated ATP sensing is required to prevent bone aging by directing mitochondrial fitness of MSCs.Journal of advanced research · 2026Article
- Adenosine ANeuropharmacology · 2025Article
- The role of maternal infections in neurodevelopmental psychiatric disorders: focus on the P2X7/NLRP3/IL-1β signalling pathway.Journal of neuroinflammation · 2025Review
- Review
- Serum P2X7 as a prognostic biomarker in acute supratentorial intracerebral hemorrhage: a two-center observational study.Frontiers in neurology · 2025Article
- Post-traumatic epilepsy: bridging pathogenesis, diagnosis, and pharmacotherapeutic strategies.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Mariana AlvesDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Laura de Diego-GarciaDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Gloria VeglianteSchool of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland.
Oscar MorenoCIC biomaGUNE, Basque research and Technology Alliance (BRTA), P° Miramon 182, 20014 San Sebastian, Gipuzkoa, Spain.
Beatriz GilDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Pedro Ramos-CabrerCIC biomaGUNE, Basque research and Technology Alliance (BRTA), P° Miramon 182, 20014 San Sebastian, Gipuzkoa, Spain.
Meghma MitraDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Ana Fernandez MartinDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Aida Menéndez-MéndezDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Yitao WangDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Nathan Ryzewski StrogulskiSchool of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland.
Meng-Juan SunDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Ciara MeliaDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Giorgia ConteDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Sandra Plaza-GarcíaCIC biomaGUNE, Basque research and Technology Alliance (BRTA), P° Miramon 182, 20014 San Sebastian, Gipuzkoa, Spain.
Igor KhalinInstitute for Stroke and Dementia Research (ISD), LMU University Hospital, Ludwig-Maximilians-University (LMU) Munich, 81377 Munich, Germany.
Xinchen TengCollege of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, China.
Nikolaus PlesnilaInstitute for Stroke and Dementia Research (ISD), LMU University Hospital, Ludwig-Maximilians-University (LMU) Munich, 81377 Munich, Germany.
Bert KleblKHAN Technology Transfer Fund I GmbH & Co. KG, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
Klaus DinkelLead Discovery Center GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
Michael HamacherAffectis Pharmaceuticals AG, Otto-Hahn-Straße 15, 44227 Dortmund, Germany.
Anindya BhattacharyaJanssen Research and Development LLC, San Diego, California, USA.
Marc CeustersJanssen Pharmaceutica NV, Beerse, Belgium.
James PalmerJanssen Research and Development LLC, San Diego, California, USA.
David J LoaneSchool of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland.
Jordi LlopCIC biomaGUNE, Basque research and Technology Alliance (BRTA), P° Miramon 182, 20014 San Sebastian, Gipuzkoa, Spain.
David C HenshallDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Tobias EngelDepartment of Physiology & Medical Physics, RCSI University of Medicine & Health Sciences, Dublin D02 YN77, Ireland.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
BrainBrain Injuries, TraumaticEpilepsy, Post-TraumaticPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7AnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLMicrogliaPositron-Emission TomographyPyridinesSeizuresTetrazoles3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridinePurinergic P2X Receptor AntagonistsPyridinesReceptors, Purinergic P2X7TetrazolesEpileptogenesisMagnetic Resonance ImagingMicrogliaP2X7 ReceptorPositron Emission TomographyPost-traumatic EpilepsyTraumatic Brain Injury
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.